Trade CTOR stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
Citius Oncology, Inc. (CTOR) is trading at US$0.75, down 4.80% today as of Oct 15, 16:00 EDT. The company has a market capitalisation of US$78.66M. Over the past 52 weeks, CTOR has traded between US$0.49 and US$2.25. On Syfe you can trade CTOR with $0 commission and add it to your watchlist.
| Previous close | US$0.78 |
|---|---|
| Market cap | US$78.66M |
| P/E ratio | 6.50 |
| 52-week range | US$0.49 – US$2.25 |
| Volume | 10.11K |
| Exchange | US |
Citius Oncology, Inc.
Citius Oncology, Inc. is a biopharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.
Year: 2024
Citius Oncology, Inc. (CTOR) stock is trading at US$0.75, -4.80% from the previous close of US$0.78.
The market cap for Citius Oncology, Inc. (CTOR) stock is approximately US$78.66M.
The price-to-earnings ratio for Citius Oncology, Inc. (CTOR) is 6.50, based on the latest reported earnings.
The 52-week high for Citius Oncology, Inc. (CTOR) stock is US$2.25.
The 52-week low for Citius Oncology, Inc. (CTOR) stock is US$0.49.
Citius Oncology, Inc. (CTOR) does not currently pay a dividend.
Stay on top of CTOR
Price moves, news and earnings — straight to your inbox.
Snapshot
Popular Stocks in Singapore
